ALCESTER, England, January 6,
2015 /PRNewswire/ --
Quanta Fluid Solutions Ltd ("Quanta" or
the "Company"), a pioneering developer of advanced haemodialysis
systems, announces it has received the CE mark for SC+, its
portable, cartridge-based haemodialysis system.
SC+ is designed to bring flexibility to dialysis patients and
physicians by supporting all treatment regimens, from
nurse-assisted care and patient self-care in-centre to home
haemodialysis. SC+ is the only portable, compact haemodialysis
system with the clinical efficacy and high flow rates of
traditional in-centre machines. The technology behind SC+ is based
on an innovative and unique design that incorporates all fluid
management activities onto a single-use disposable cartridge.
Quanta is also pleased to announce that it has raised additional
funds expanding its recent investment round to a total of £29
million. The round was led by new investor ALIAD, the venture
capital investment vehicle of Air Liquide SA (Paris: AI), and
included participation by additional new investors Seventure
Partners and Kuwait Life Sciences Company, as well as existing
investors Wellington Partners, Seroba Kernel, NBGI Ventures, b-to-v
Partners and IMI plc (LSE: IMI).
John E. Milad, Chief Executive
Officer of Quanta,
said: "This is an
exciting time for
Quanta. Obtaining the CE mark for SC+ is
a major milestone forus and is a
testament to the ingenuity and engineering excellence of our team.
SC+ is a revolutionary dialysis
system based around a novel single-use disposable
cartridge. Our system will provide
meaningful benefits to patients and healthcare providers in terms
of ease-of-use, flexibility and
performance. 2014 was a transformational year
for Quanta, and we
are now strongly positioned to introduce SC+ for clinical
use in 2015."
Professor John
Agar, a practicing clinical nephrologist,
Clinical Conjoint Professor of Medicine at Deakin University School of Medicine at the Geelong
Hospital, Barwon Health and Member of Quanta's
Medical Advisory Board,
said: "Quanta's SC+ is the first
real advance in dialysis system choice in a decade and a half.
While small, light, and truly portable, it is still at its heart, a
single pass dialysis system providing efficient and comparable
dialysis to current technologies. SC+ has the
benefit of transferability from centre to home, and from home to
centre, which gives valuable and flexible
treatment options for physicians, patients and care givers. This is
a truly game-changing technology."
About Quanta
Quanta is developing advanced haemodialysis systems for use in
the clinic and the home. The Company's cartridge-based solution SC+
is the only portable, compact haemodialysis system with the
clinical efficacy and high flow rates of traditional machines. SC+
is designed to offer ease-of-use and flexibility, facilitating
self-care and supporting dialysis patients across the entire
continuum of care.
Quanta is privately owned and based in Alcester, UK. The Company was founded in 2008
as a spin out from the FTSE 100 engineering company IMI plc, with
funding provided by a group of leading venture capital investors
specialised in healthcare: NBGI Ventures, Wellington Partners,
Seroba Kernel and b-to-v Partners, and more recently ALIAD,
Seventure Partners and Kuwait Life Sciences Company.
Quanta is dedicated to creating a paradigm shift in renal care
and to improving the lives of dialysis patients.
For more information please visit: http://www.quantafs.com.
About End Stage Renal Disease and Haemodialysis:
Lifestyle choices, modern diet and increased life expectancy are
all negatively impacting renal health across the globe and End
Stage Renal Disease affects millions of patients worldwide.
Haemodialysis is a life-saving treatment delivered to an estimated
2 million people globally-with this figure expected to double in
the next decade.
At present, haemodialysis is primarily provided by specialist
clinics and centres. However this means that the patient is not in
control of when they can dialyse. It is clinically proven that more
regular dialysis improves outcomes and quality of life for the
patient, and a number of studies have shown that 30-40% of patients
would be capable of performing self-dialysis.
Issues of patient benefit, cost and clinic capacity are driving
the growth of home and self-care modalities of haemodialysis, but a
major factor limiting the growth of self-care and home
haemodialysis is the lack of convenient, portable and easy-to-use
dialysis systems. SC+ addresses these issues and puts the
patient at the centre, allowing them to take greater control of
their treatment.
For more information about Quanta, please contact:
Quanta
John E. Milad,
Chief Executive Officer
T: +44-(0)1789-400043
E: john.milad@quantafs.com
Consilium Strategic Communications
Amber Bielecka / Mary-Jane Elliott / Matthew
Neal / Lindsey Neville
T: +44-(0)203-709-5708
E:quanta@consilium-comms.com
SOURCE Quanta